KA/EN
Register
Medicines reference
Search
Search
Product

Bravecto

Favourites

Fluralaner · Intervet International B.V., MSD Animal Health

8 forms: chewable tablet, spot-on. In force in Georgia: 5 of 8 (veterinary register).

Forms and doses5 of 8 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
112.5 mg, Chewable tablet · Dog 2–4.5 kg Dog 2–4.5 kg 1 tablet
Give one whole 112.5 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 · Indication-specific; flea control at 12-week intervals		 Indication-specific; flea control at 12-week intervals Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 112.5 მგ საღეჭი ტაბლეტი ძალიან პატარა ზომის ძაღლებისთვის (2-4.5 კგ)
№ 369-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 112.5 mg, Chewable tablet

fluralaner 112.5 mg, chewable tablet for dogs 2-4.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.8/10
Very good
vetman assessment

Bravecto

112.5 mg, fluralaner 112.5 mg, chewable tablet for dogs 2-4.5 kg
Assessed clinical scopeDog · Labelled treatment and sustained control of susceptible flea and tick infestations in dogs within the presentation's exact weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment
vetman score 8.8/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 369-11 · Verified on 21 Oct 2026

A highly effective, long-interval flea and tick option with excellent regulatory support; select the exact whole-tablet weight band and use neurologic caution.

Regulatory and scientific credibility9.5/10

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Clinical efficacy9.0/10

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

Safety and tolerability7.5/10

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

Clinical practicality9.5/10

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in hypersensitivity to fluralaner or an excipient.
  • Use with caution in dogs with pre-existing epilepsy; counsel for tremor, ataxia or seizures.
  • Use only the whole tablet assigned to this presentation's weight band (2-4.5 kg); do not divide the tablet. Do not use below 8 weeks or 2 kg, and do not repeat at intervals shorter than 8 weeks.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Fluralaner field RCT2014
  4. FDA 20262026
  5. EMA pharmacovigilance 20252026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner112.5 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Intervet International B.V. · Netherlands
Manufacturer (register)
GesmbH Intervet GesmbH MAH: ინტერვეტ ინტერნაციონალ ბ.ვ./Intervet International B.V. (Netherlands), Austria
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 998, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 112.5 მგ საღეჭი ტაბლეტი ძალიან პატარა ზომის ძაღლებისთვის (2-4.5 კგ)
№ 369-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-426
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give one whole 112.5 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 Dog 2–4.5 kg By mouth Indication-specific; flea control at 12-week intervals
EU UPD Bravecto 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Bravecto chewable tablets for dogs - combined product information
EU Union Product Database, 2026
112.5 mg, Spot-on · Cat 1.2–2.8 kg Cat 1.2–2.8 kg 1 pipette
The veterinary medicinal product should be administered in accordance with the following table (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight) For optimal control of tick and flea infestation, the veterinary medicinal product should be administered at intervals of 12 weeks. should not be administered at intervals shorter than 8 weeks In the absence of available data, this veterinary medicinal product should not be used on kittens less than 9 weeks old and /or cats weighing less than 1.2 kg. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian. Uncommon Ataxia, Convulsion
 · every 12 weeks		 every 12 weeks Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
112.5 mg, Spot-on · Dog Any weight Dog Any weight No dose for this species
This pipette is labelled only for cats; no canine dose is established.
 - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 112.5 mg, Spot-on

fluralaner 112.5 mg, spot-on solution for cats 1.2-2.8 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.4/10
Very good
vetman assessment

Bravecto

112.5 mg, fluralaner 112.5 mg, spot-on solution for cats 1.2-2.8 kg
Assessed clinical scopeCat · Full cat label: treatment of Ctenocephalides felis flea and Ixodes ricinus tick infestations with 12-week activity, use in a flea-allergy dermatitis strategy, and single-dose treatment of Otodectes cynotis ear mites within the exact pipette weight band · On the skin
Care settingVeterinary-selected outpatient ectoparasite treatment after exact weighing and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective long-interval feline spot-on with strong exact-product regulation and direct cat studies across its full flea, tick, FAD-strategy and ear-mite label. Its absence from the Georgian register, application-site reactions and uncommon-to-very-rare neurologic events remain material limitations.

Regulatory and scientific credibility8.5/10

The exact pipette is supported by a current detailed VMD SPC and active EU, UK and US authorisations. It is explicitly not registered in the checked Georgian veterinary register, which limits local regulatory standing without weakening the foreign dossier.

Clinical efficacy9.0/10

Randomised field evidence supports about 99% flea-count reduction through 12 weeks after one topical dose; controlled and natural-infestation studies support the ear-mite claim. Tick efficacy and the exact species-duration scope are regulator assessed, but parasites must feed and transmission cannot be excluded.

Safety and tolerability7.5/10

Mild transient application-site reactions are common; tremor, lethargy, anorexia, vomiting or hypersalivation are uncommon, and ataxia or convulsion are very rare. Pregnancy and lactation safety is unestablished, and human skin, eye, ingestion and flammability precautions are substantial.

Clinical practicality8.8/10

One exact weight-banded pipette provides a 12-week flea/tick interval and a single ear-mite dose. Accurate skin placement, gloves, prevention of grooming and up to 48 hours before close contact add technique; cats above 6.25 kg require two application spots.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with hypersensitivity to fluralaner or an excipient. Apply only to intact skin; avoid the eyes, never give orally and prevent recently treated cats from grooming each other.
  • Do not use below 9 weeks of age or below 1.2 kg. Do not repeat at intervals shorter than 8 weeks; routine flea/tick retreatment is risk-based, with 12 weeks the labelled optimal interval.
  • Monitor the application site for erythema, pruritus or alopecia and the cat for tremor, lethargy, anorexia, vomiting, hypersalivation, ataxia or convulsion; persistent or marked signs require reassessment.
  • Safety during pregnancy and lactation is not established; use only after the responsible veterinarian documents a benefit-risk assessment.
  • Wear the supplied gloves. Avoid skin and eye exposure, ingestion and ignition sources; keep children and close contact, including cuddling or shared bedding, away until the application site is no longer noticeable, which can take up to 48 hours.
  • Fleas and ticks must attach and feed, so vector-borne transmission cannot be excluded. Confirm parasite risk, address infected household animals and avoid unnecessary or underdosed use that can select resistance.
  • Use the complete 112.5 mg pipette only for cats 1.2-2.8 kg and apply in one spot at the skull base. For ear mites, use one dose and re-examine at 28 days because an alternative treatment may be needed.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Georgia NFA register 20262026
  4. Feline fluralaner flea field RCT2017
  5. Fluralaner ear-mite RCT2017
  6. Fluralaner flea/ear-mite trial2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner112.5 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
MSD Animal Health · United States
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-459
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 pipette
The veterinary medicinal product should be administered in accordance with the following table (corresponding to a dose of 40 – 94 mg fluralaner/kg body weight) For optimal control of tick and flea infestation, the veterinary medicinal product should be administered at intervals of 12 weeks. should not be administered at intervals shorter than 8 weeks In the absence of available data, this veterinary medicinal product should not be used on kittens less than 9 weeks old and /or cats weighing less than 1.2 kg. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only accordingly to the benefit/risk assessment by the responsible veterinarian. Uncommon Ataxia, Convulsion
 Cat 1.2–2.8 kg On the skin every 12 weeks Product label (SPC)
No dose for this species
This pipette is labelled only for cats; no canine dose is established.
 Dog Any weight On the skin - Product label (SPC)
250 mg, Chewable tablet · Dog 4.5–10 kg Dog 4.5–10 kg 1 tablet
Give one whole 250.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 · Indication-specific; flea control at 12-week intervals		 Indication-specific; flea control at 12-week intervals Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 250 მგ საღეჭი ტაბლეტი პატარა ზომის ძაღლებისთვის (>4.5-10 კგ)
№ 368-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 250 mg, Chewable tablet

fluralaner 250 mg, chewable tablet for dogs 4.5-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.8/10
Very good
vetman assessment

Bravecto

250 mg, fluralaner 250 mg, chewable tablet for dogs 4.5-10 kg
Assessed clinical scopeDog · Labelled treatment and sustained control of susceptible flea and tick infestations in dogs within the presentation's exact weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment
vetman score 8.8/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 368-11 · Verified on 21 Oct 2026

A highly effective, long-interval flea and tick option with excellent regulatory support; select the exact whole-tablet weight band and use neurologic caution.

Regulatory and scientific credibility9.5/10

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Clinical efficacy9.0/10

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

Safety and tolerability7.5/10

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

Clinical practicality9.5/10

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in hypersensitivity to fluralaner or an excipient.
  • Use with caution in dogs with pre-existing epilepsy; counsel for tremor, ataxia or seizures.
  • Use only the whole tablet assigned to this presentation's weight band (>4.5-10 kg); do not divide the tablet. Do not use below 8 weeks or 2 kg, and do not repeat at intervals shorter than 8 weeks.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Fluralaner field RCT2014
  4. FDA 20262026
  5. EMA pharmacovigilance 20252026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner250 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Intervet International B.V. · Netherlands
Manufacturer (register)
GesmbH Intervet GesmbH MAH: ინტერვეტ ინტერნაციონალ ბ.ვ./Intervet International B.V. (Netherlands), Austria
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 997, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 250 მგ საღეჭი ტაბლეტი პატარა ზომის ძაღლებისთვის (>4.5-10 კგ)
№ 368-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-426
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give one whole 250.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 Dog 4.5–10 kg By mouth Indication-specific; flea control at 12-week intervals
EU UPD Bravecto 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Bravecto chewable tablets for dogs - combined product information
EU Union Product Database, 2026
250 mg, Spot-on · Cat 2.8–6.25 kg Cat 2.8–6.25 kg 1 pipette
corresponding to a dose of 40 – 94 mg fluralaner/kg body weight The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
 · every 12 weeks		 every 12 weeks Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
250 mg, Spot-on · Dog Any weight Dog Any weight No dose for this species
This pipette is labelled only for cats; no canine dose is established.
 - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 250 mg, Spot-on

fluralaner 250 mg, spot-on solution for cats >2.8-6.25 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.4/10
Very good
vetman assessment

Bravecto

250 mg, fluralaner 250 mg, spot-on solution for cats >2.8-6.25 kg
Assessed clinical scopeCat · Full cat label: treatment of Ctenocephalides felis flea and Ixodes ricinus tick infestations with 12-week activity, use in a flea-allergy dermatitis strategy, and single-dose treatment of Otodectes cynotis ear mites within the exact pipette weight band · On the skin
Care settingVeterinary-selected outpatient ectoparasite treatment after exact weighing and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective long-interval feline spot-on with strong exact-product regulation and direct cat studies across its full flea, tick, FAD-strategy and ear-mite label. Its absence from the Georgian register, application-site reactions and uncommon-to-very-rare neurologic events remain material limitations.

Regulatory and scientific credibility8.5/10

The exact pipette is supported by a current detailed VMD SPC and active EU, UK and US authorisations. It is explicitly not registered in the checked Georgian veterinary register, which limits local regulatory standing without weakening the foreign dossier.

Clinical efficacy9.0/10

Randomised field evidence supports about 99% flea-count reduction through 12 weeks after one topical dose; controlled and natural-infestation studies support the ear-mite claim. Tick efficacy and the exact species-duration scope are regulator assessed, but parasites must feed and transmission cannot be excluded.

Safety and tolerability7.5/10

Mild transient application-site reactions are common; tremor, lethargy, anorexia, vomiting or hypersalivation are uncommon, and ataxia or convulsion are very rare. Pregnancy and lactation safety is unestablished, and human skin, eye, ingestion and flammability precautions are substantial.

Clinical practicality8.8/10

One exact weight-banded pipette provides a 12-week flea/tick interval and a single ear-mite dose. Accurate skin placement, gloves, prevention of grooming and up to 48 hours before close contact add technique; cats above 6.25 kg require two application spots.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with hypersensitivity to fluralaner or an excipient. Apply only to intact skin; avoid the eyes, never give orally and prevent recently treated cats from grooming each other.
  • Do not use below 9 weeks of age or below 1.2 kg. Do not repeat at intervals shorter than 8 weeks; routine flea/tick retreatment is risk-based, with 12 weeks the labelled optimal interval.
  • Monitor the application site for erythema, pruritus or alopecia and the cat for tremor, lethargy, anorexia, vomiting, hypersalivation, ataxia or convulsion; persistent or marked signs require reassessment.
  • Safety during pregnancy and lactation is not established; use only after the responsible veterinarian documents a benefit-risk assessment.
  • Wear the supplied gloves. Avoid skin and eye exposure, ingestion and ignition sources; keep children and close contact, including cuddling or shared bedding, away until the application site is no longer noticeable, which can take up to 48 hours.
  • Fleas and ticks must attach and feed, so vector-borne transmission cannot be excluded. Confirm parasite risk, address infected household animals and avoid unnecessary or underdosed use that can select resistance.
  • Use the complete 250 mg pipette only for cats above 2.8 kg through 6.25 kg and apply in one spot at the skull base. For ear mites, use one dose and re-examine at 28 days because an alternative treatment may be needed.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Georgia NFA register 20262026
  4. Feline fluralaner flea field RCT2017
  5. Fluralaner ear-mite RCT2017
  6. Fluralaner flea/ear-mite trial2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner250 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
MSD Animal Health · United States
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-459
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 pipette
corresponding to a dose of 40 – 94 mg fluralaner/kg body weight The safety of the veterinary medicinal product has not been established during pregnancy and lactation.
 Cat 2.8–6.25 kg On the skin every 12 weeks Product label (SPC)
No dose for this species
This pipette is labelled only for cats; no canine dose is established.
 Dog Any weight On the skin - Product label (SPC)
500 mg, Chewable tablet · Dog 10–20 kg Dog 10–20 kg 1 tablet
Give one whole 500.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 · Indication-specific; flea control at 12-week intervals		 Indication-specific; flea control at 12-week intervals Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 500 მგ საღეჭი ტაბლეტი საშუალო ზომის ძაღლებისთვის (>10-20 კგ)
№ 367-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 500 mg, Chewable tablet

fluralaner 500 mg, chewable tablet for dogs 10-20 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.8/10
Very good
vetman assessment

Bravecto

500 mg, fluralaner 500 mg, chewable tablet for dogs 10-20 kg
Assessed clinical scopeDog · Labelled treatment and sustained control of susceptible flea and tick infestations in dogs within the presentation's exact weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment
vetman score 8.8/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 367-11 · Verified on 21 Oct 2026

A highly effective, long-interval flea and tick option with excellent regulatory support; select the exact whole-tablet weight band and use neurologic caution.

Regulatory and scientific credibility9.5/10

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Clinical efficacy9.0/10

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

Safety and tolerability7.5/10

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

Clinical practicality9.5/10

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in hypersensitivity to fluralaner or an excipient.
  • Use with caution in dogs with pre-existing epilepsy; counsel for tremor, ataxia or seizures.
  • Use only the whole tablet assigned to this presentation's weight band (>10-20 kg); do not divide the tablet. Do not use below 8 weeks or 2 kg, and do not repeat at intervals shorter than 8 weeks.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Fluralaner field RCT2014
  4. FDA 20262026
  5. EMA pharmacovigilance 20252026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner500 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Intervet International B.V. · Netherlands
Manufacturer (register)
GesmbH Intervet GesmbH MAH: ინტერვეტ ინტერნაციონალ ბ.ვ./Intervet International B.V. (Netherlands), Austria
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 996, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 500 მგ საღეჭი ტაბლეტი საშუალო ზომის ძაღლებისთვის (>10-20 კგ)
№ 367-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-426
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give one whole 500.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 Dog 10–20 kg By mouth Indication-specific; flea control at 12-week intervals
EU UPD Bravecto 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Bravecto chewable tablets for dogs - combined product information
EU Union Product Database, 2026
500 mg, Spot-on · Cat 6.25–12.5 kg Cat 6.25–12.5 kg 1 pipette
corresponding to a dose of 40 – 94 mg fluralaner/kg body weight in two spots on cats greater than 6.25 kg body weight
 · every 12 weeks		 every 12 weeks Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
500 mg, Spot-on · Dog Any weight Dog Any weight No dose for this species
This pipette is labelled only for cats; no canine dose is established.
 - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 500 mg, Spot-on

fluralaner 500 mg, spot-on solution for cats >6.25-12.5 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.4/10
Very good
vetman assessment

Bravecto

500 mg, fluralaner 500 mg, spot-on solution for cats >6.25-12.5 kg
Assessed clinical scopeCat · Full cat label: treatment of Ctenocephalides felis flea and Ixodes ricinus tick infestations with 12-week activity, use in a flea-allergy dermatitis strategy, and single-dose treatment of Otodectes cynotis ear mites within the exact pipette weight band · On the skin
Care settingVeterinary-selected outpatient ectoparasite treatment after exact weighing and parasite-risk assessment
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: No · Verified on 15 Oct 2026

A highly effective long-interval feline spot-on with strong exact-product regulation and direct cat studies across its full flea, tick, FAD-strategy and ear-mite label. Its absence from the Georgian register, application-site reactions and uncommon-to-very-rare neurologic events remain material limitations.

Regulatory and scientific credibility8.5/10

The exact pipette is supported by a current detailed VMD SPC and active EU, UK and US authorisations. It is explicitly not registered in the checked Georgian veterinary register, which limits local regulatory standing without weakening the foreign dossier.

Clinical efficacy9.0/10

Randomised field evidence supports about 99% flea-count reduction through 12 weeks after one topical dose; controlled and natural-infestation studies support the ear-mite claim. Tick efficacy and the exact species-duration scope are regulator assessed, but parasites must feed and transmission cannot be excluded.

Safety and tolerability7.5/10

Mild transient application-site reactions are common; tremor, lethargy, anorexia, vomiting or hypersalivation are uncommon, and ataxia or convulsion are very rare. Pregnancy and lactation safety is unestablished, and human skin, eye, ingestion and flammability precautions are substantial.

Clinical practicality8.8/10

One exact weight-banded pipette provides a 12-week flea/tick interval and a single ear-mite dose. Accurate skin placement, gloves, prevention of grooming and up to 48 hours before close contact add technique; cats above 6.25 kg require two application spots.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use with hypersensitivity to fluralaner or an excipient. Apply only to intact skin; avoid the eyes, never give orally and prevent recently treated cats from grooming each other.
  • Do not use below 9 weeks of age or below 1.2 kg. Do not repeat at intervals shorter than 8 weeks; routine flea/tick retreatment is risk-based, with 12 weeks the labelled optimal interval.
  • Monitor the application site for erythema, pruritus or alopecia and the cat for tremor, lethargy, anorexia, vomiting, hypersalivation, ataxia or convulsion; persistent or marked signs require reassessment.
  • Safety during pregnancy and lactation is not established; use only after the responsible veterinarian documents a benefit-risk assessment.
  • Wear the supplied gloves. Avoid skin and eye exposure, ingestion and ignition sources; keep children and close contact, including cuddling or shared bedding, away until the application site is no longer noticeable, which can take up to 48 hours.
  • Fleas and ticks must attach and feed, so vector-borne transmission cannot be excluded. Confirm parasite risk, address infected household animals and avoid unnecessary or underdosed use that can select resistance.
  • Use the complete 500 mg pipette only for cats above 6.25 kg through 12.5 kg and apply in two spots at the skull base; above 12.5 kg requires a veterinarian-selected two-pipette combination. For ear mites, use one dose and re-examine at 28 days because an alternative treatment may be needed.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Georgia NFA register 20262026
  4. Feline fluralaner flea field RCT2017
  5. Fluralaner ear-mite RCT2017
  6. Fluralaner flea/ear-mite trial2019
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner500 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
MSD Animal Health · United States
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-459
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 pipette
corresponding to a dose of 40 – 94 mg fluralaner/kg body weight in two spots on cats greater than 6.25 kg body weight
 Cat 6.25–12.5 kg On the skin every 12 weeks Product label (SPC)
No dose for this species
This pipette is labelled only for cats; no canine dose is established.
 Dog Any weight On the skin - Product label (SPC)
1000 mg, Chewable tablet · Dog 20–40 kg Dog 20–40 kg 1 tablet
Give one whole 1000.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 · Indication-specific; flea control at 12-week intervals		 Indication-specific; flea control at 12-week intervals Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 1000 მგ საღეჭი ტაბლეტი დიდი ზომის ძაღლებისთვის (>20-40 კგ)
№ 366-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 1000 mg, Chewable tablet

fluralaner 1000 mg, chewable tablet for dogs 20-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.8/10
Very good
vetman assessment

Bravecto

1000 mg, fluralaner 1000 mg, chewable tablet for dogs 20-40 kg
Assessed clinical scopeDog · Labelled treatment and sustained control of susceptible flea and tick infestations in dogs within the presentation's exact weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment
vetman score 8.8/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 366-11 · Verified on 21 Oct 2026

A highly effective, long-interval flea and tick option with excellent regulatory support; select the exact whole-tablet weight band and use neurologic caution.

Regulatory and scientific credibility9.5/10

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Clinical efficacy9.0/10

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

Safety and tolerability7.5/10

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

Clinical practicality9.5/10

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in hypersensitivity to fluralaner or an excipient.
  • Use with caution in dogs with pre-existing epilepsy; counsel for tremor, ataxia or seizures.
  • Use only the whole tablet assigned to this presentation's weight band (>20-40 kg); do not divide the tablet. Do not use below 8 weeks or 2 kg, and do not repeat at intervals shorter than 8 weeks.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Fluralaner field RCT2014
  4. FDA 20262026
  5. EMA pharmacovigilance 20252026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner1000 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Intervet International B.V. · Netherlands
Manufacturer (register)
GesmbH Intervet GesmbH MAH: ინტერვეტ ინტერნაციონალ ბ.ვ./Intervet International B.V. (Netherlands), Austria
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 995, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 1000 მგ საღეჭი ტაბლეტი დიდი ზომის ძაღლებისთვის (>20-40 კგ)
№ 366-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-426
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give one whole 1000.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 Dog 20–40 kg By mouth Indication-specific; flea control at 12-week intervals
EU UPD Bravecto 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Bravecto chewable tablets for dogs - combined product information
EU Union Product Database, 2026
1400 mg, Chewable tablet · Dog 40–56 kg Dog 40–56 kg 1 tablet
Give one whole 1400.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 · Indication-specific; flea control at 12-week intervals		 Indication-specific; flea control at 12-week intervals Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 1400 მგ საღეჭი ტაბლეტი ძალიან დიდი ზომის ძაღლებისთვის (>40-56 კგ)
№ 365-11
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Bravecto 1400 mg, Chewable tablet

fluralaner 1400 mg, chewable tablet for dogs 40-56 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.8/10
Very good
vetman assessment

Bravecto

1400 mg, fluralaner 1400 mg, chewable tablet for dogs 40-56 kg
Assessed clinical scopeDog · Labelled treatment and sustained control of susceptible flea and tick infestations in dogs within the presentation's exact weight band · By mouth
Care settingVeterinary-selected outpatient ectoparasite treatment
vetman score 8.8/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 365-11 · Verified on 21 Oct 2026

A highly effective, long-interval flea and tick option with excellent regulatory support; select the exact whole-tablet weight band and use neurologic caution.

Regulatory and scientific credibility9.5/10

The exact chewable range is centrally authorised in the EU, has current official product information, FDA labelling and active Georgian veterinary registration for all five strengths.

Clinical efficacy9.0/10

Randomised field evidence and regulatory assessment support very high flea and tick efficacy from one correctly dosed tablet for up to 12 weeks; duration varies for particular tick species and transmission is not instantaneous.

Safety and tolerability7.5/10

The safety profile is well characterised and most adverse effects are uncommon or very rare, but gastrointestinal reactions, pruritus and rare neurologic reactions including tremor, ataxia and convulsion require explicit caution, especially with pre-existing epilepsy.

Clinical practicality9.5/10

A single palatable tablet with food provides a long interval and is operationally simple; accurate weighing and whole-tablet selection are essential because tablets must not be divided.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not use in hypersensitivity to fluralaner or an excipient.
  • Use with caution in dogs with pre-existing epilepsy; counsel for tremor, ataxia or seizures.
  • Use only the whole tablet assigned to this presentation's weight band (>40-56 kg); do not divide the tablet. Do not use below 8 weeks or 2 kg, and do not repeat at intervals shorter than 8 weeks.
Assessment sources
  1. VMD SPC 20252025
  2. EMA Bravecto EPAR2026
  3. Fluralaner field RCT2014
  4. FDA 20262026
  5. EMA pharmacovigilance 20252026
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Fluralaner1400 mg
Formulation Type
Chewable tablet
Administration route
By mouth
Manufacturer
Intervet International B.V. · Netherlands
Manufacturer (register)
GesmbH Intervet GesmbH MAH: ინტერვეტ ინტერნაციონალ ბ.ვ./Intervet International B.V. (Netherlands), Austria
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 994, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ბრავექტო™ 1400 მგ საღეჭი ტაბლეტი ძალიან დიდი ზომის ძაღლებისთვის (>40-56 კგ)
№ 365-11
Verified on: 21 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US Yes, veterinary
№ NADA 141-426
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
1 tablet
Give one whole 1400.0 mg chewable tablet at or around feeding time. This provides 25-56 mg/kg within the labelled weight band. Do not break or divide the tablet. Tick retreatment depends on tick species and professional advice. Do not administer at intervals shorter than 8 weeks. Do not use in puppies under 8 weeks or dogs under 2 kg because safety data are unavailable. Use with caution in dogs with pre-existing epilepsy. For dogs over 56 kg, use the combination of two tablets that most closely matches body weight.
 Dog 40–56 kg By mouth Indication-specific; flea control at 12-week intervals
EU UPD Bravecto 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Bravecto chewable tablets for dogs - combined product information
EU Union Product Database, 2026
Active substance doses, with sources
Active substance Fluralaner
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
25–56 mg/kg Dog Maintenance By mouth every 12 weeks
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Bravecto 112.5 mg chewable tablets for very small dogs (2 - 4.5 kg) - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Warning (Dog)
    Adverse events have been reported following use in breeding females. Before use in breeding female dogs, refer to Post-Approval Experience and Animal Safety sections. In some cases, birth defects (including limb deformities and cleft palate), stillbirth, and abortion have been reported after treatment of breeding females. The safety of the veterinary medicinal product in breeding, pregnant and lactating dogs has been demonstrated. Can be used in breeding, pregnant and lactating dogs.
    Sources: VMD SPC · VMD · FDA
  • Warning (Dog)
    In the absence of available data, the veterinary medicinal product should not be used on puppies less than 8 weeks old and /or dogs weighing less than 2 kg.
    Sources: VMD SPC · VMD
  • Caution (Dog)
    Fluralaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isoxazoline class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Use with caution in dogs with pre-existing epilepsy. Muscle tremor, Ataxia, Convulsion.
    Sources: VMD SPC · VMD · FDA
  • Caution (Dog)
    The minimum age for fluralaner depends on the product label. Some labels permit use from 8 weeks, whereas the US 12-week product claim applies only from 6 months of age and 2 kg body weight; 12-week efficacy has not been demonstrated in younger puppies.
    Sources: VMD SPC · VMD · FDA

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (80 more) Hide additional products

Same therapeutic group 80

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗